Last update June 4, 2024
Compatible
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Valsartan in other languages or writings:
Valsartan belongs to these groups or families:
Main tradenames from several countries containing Valsartan in its composition:
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by IHAN of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Valsartan is an angiotensin II receptor antagonist (ARA) with actions similar to those of losartan. It is indicated in the treatment of hypertension, left ventricular dysfunction after myocardial infarction and in heart failure. Oral administration once or twice daily.
Its pharmacokinetic data (high percentage of protein binding, large volume of distribution and moderately high molecular weight) explain the null passage into breast milk observed, below the limit of detection. (Falconi 2024)
In addition, its low oral bioavailability makes it difficult for it to pass into infant plasma from ingested breast milk, except in premature infants and the immediate neonatal period in which there may be greater intestinal permeability.
Dos lactantes cuyas madres tomaban sacubitril/valsartan no presentaron ningún problema. (Hale)